Turkiye Klinikleri Archives of Lung最新文献_第3页

First HPV 67+ and HPV 16+ Endobronchial and Laryngeal Squamous Cell Papilloma Detected in the Literature 文献中首次发现hpv67 +和hpv16 +支气管和喉内鳞状细胞乳头状瘤

Turkiye Klinikleri Archives of Lung Pub Date : 1900-01-01 DOI: 10.5336/archlung.2022-88175

Hatice Arzu Uçar, O. Yazıcı, Nesibe Kahraman Çetin

引用次数: 0

The Relationship Between Demographic and Clinical Characteristics of Hospitalized COVID-19 Patients with Prognosis: Cross-Sectional Study 住院COVID-19患者人口学和临床特征与预后的关系:横断面研究

Turkiye Klinikleri Archives of Lung Pub Date : 1900-01-01 DOI: 10.5336/archlung.2022-90348

Serdanur Özdemi̇r, B. Yılmaz Kara, A. Gümüş, Uğur Kesimal

引用次数: 0

The Change in Anxiety and Depression Levels of Chronic Obstructive Pulmonary Disease Patients During the COVID-19 Pandemic Period: A Follow-Up Study COVID-19大流行期间慢性阻塞性肺疾病患者焦虑和抑郁水平变化的随访研究

Turkiye Klinikleri Archives of Lung Pub Date : 1900-01-01 DOI: 10.5336/archlung.2022-88122

Nurgül Bozkurt, A. Bozkurt

{"title":"The Change in Anxiety and Depression Levels of Chronic Obstructive Pulmonary Disease Patients During the COVID-19 Pandemic Period: A Follow-Up Study","authors":"Nurgül Bozkurt, A. Bozkurt","doi":"10.5336/archlung.2022-88122","DOIUrl":"https://doi.org/10.5336/archlung.2022-88122","url":null,"abstract":"Objective: The Covid-19 pandemic has led to the postponement of applications to health institutions due to the risk of transmission of the disease in individuals with chronic diseases, and to an increase in the level of anxiety due to its more severe/fatal course when infected. Chronic obstructive pulmonary patients are among the most affected groups. In this study, the change in anxiety/depression status during the pandemic process in chronic obstructive pulmonary patients was investigated. Material and Methods: The study was conducted in chronic obstructive pulmonary patients anxiety/depression scores were measured by applying the \"Hospital Anxiety/Depression Scale\"(HAD) before pandemia (November2019/March-2020). With the start of the pandemic process in our country in March2020, in order to determine how our patients were affected by the pandemic, the HAD scale was repeated by reaching the same patients by phone in the 18 months of the pandemic (September/2021). The anxiety/depression scores of the patients before and 18 months of the pandemic were compared. The data were analyzed in SPSS 22.0 program. In comparison, X2 and t-tests were used, independent groups.","PeriodicalId":221551,"journal":{"name":"Turkiye Klinikleri Archives of Lung","volume":"27 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131353399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current Treatment Strategies of COVID-19 当前COVID-19的治疗策略

Turkiye Klinikleri Archives of Lung Pub Date : 1900-01-01 DOI: 10.5336/archlung.2020-79896

Özge Aydın Güçlü, A. Görek Dilektaşlı

{"title":"Current Treatment Strategies of COVID-19","authors":"Özge Aydın Güçlü, A. Görek Dilektaşlı","doi":"10.5336/archlung.2020-79896","DOIUrl":"https://doi.org/10.5336/archlung.2020-79896","url":null,"abstract":"On 31 December 2019, the Wuhan Municipal Committee of Health and Healthcare (Hubei Province, China) reported that there were 27 cases of pneumonia of unknown origin with symptoms starting on the 8 December. On 7 January 2020, the Chinese authorities identified that the agent causing the outbreak was a new type of virus of the Coronaviridae family, temporarily called 'new coronavirus, 2019-nCoV'. On January 30th, 2020, the World Health Organisation (WHO) declared the outbreak an international emergency and described it as a pandemic in March 2020. While it was previously referred to as 2019-nCoV by WHO, on February 11, 2020, the disease was named as severe acute respiratory syndrome-coronavirus2. The disease was confirmed to have reached Turkey on 11 March 2020, after a patient who had returned to Turkey from Europe, tested positive. The most appropriate treatment approach to treating COVID-19 remains unclear. Current treatment protocols are based on limited data and are evolving rapidly as clinical data emerge. A large volume of data and publications from randomized controlled trials, observational cohorts, and case series are emerging promptly, some in peer-reviewed journals, others as manuscripts that have not yet been peer reviewed. The Republic of Turkey Ministry of Health invited the specialties societies to prepare a clinical protocol for the management of COVID-19. The Turkish Pandemic Working Group prepare the present recommendations with the evidence available at the time of preparing them. It is aimed to summarize the treatment management of COVID-19 in line with the current treatment recommendations in national and international guidelines. Keywords: COVID-19;pandemic;treatment.","PeriodicalId":221551,"journal":{"name":"Turkiye Klinikleri Archives of Lung","volume":"344 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123104929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adherence to Inhaler Treatments: Statement of Patients and Their Relatives: Cross-Sectional Study 依从吸入器治疗:患者及其亲属的陈述:横断面研究

Turkiye Klinikleri Archives of Lung Pub Date : 1900-01-01 DOI: 10.5336/archlung.2021-87724

F. Aksu, K. Aksu, T. N. Tezvergil, Ali Fırıncıoğluları

引用次数: 0

Risk Factors for Delayed Pleuroparenchymal Complications in Patients with Rib Fractures: Descriptive Research 肋骨骨折患者迟发性胸膜实质并发症的危险因素:描述性研究

Turkiye Klinikleri Archives of Lung Pub Date : 1900-01-01 DOI: 10.5336/archlung.2022-92647

H. Esme

引用次数: 0

Economic Burden and Key Cost Drivers of Managing Hospitalized Chronic Obstructive Pulmonary Disease Patients Admitted with an Exacerbation in Türkiye: A Cost of Illness Study from Payer Perspective 经济负担和主要成本驱动因素管理慢性阻塞性肺疾病住院患者入院加重:从付款人的角度疾病成本研究

Turkiye Klinikleri Archives of Lung Pub Date : 1900-01-01 DOI: 10.5336/archlung.2022-88430

M. Polatlı, E. Öksüz, S. Malhan

{"title":"Economic Burden and Key Cost Drivers of Managing Hospitalized Chronic Obstructive Pulmonary Disease Patients Admitted with an Exacerbation in Türkiye: A Cost of Illness Study from Payer Perspective","authors":"M. Polatlı, E. Öksüz, S. Malhan","doi":"10.5336/archlung.2022-88430","DOIUrl":"https://doi.org/10.5336/archlung.2022-88430","url":null,"abstract":"ABS TRACT Objective: To estimate the economic burden and key cost drivers of managing exacerbated and hospitalized chronic obstructive pulmonary disease (COPD) patients in Türkiye. Material and Methods: This cost of illness study was based on an estimation of per patient annual direct medical costs for the management of exacerbated and hospitalized COPD patients in Türkiye from a payer perspective. The average per patient direct medical cost was calculated based on cost items related to out- patient visits, diagnostic laboratory and radiological tests, hospitalizations and interventions, training and rehabilitation, drug treatment and equip- ment, drug-related adverse events, and co-morbidities/complications. Results: Based on average annual per patient costs calculated for outpatient admission ($88.5), laboratory and radiological tests ($68.6), hospitalizations and interventions/training/rehabilitation ($1,181.3), drug treat- ment/equipment ($1,088.0), co-morbidities/complications ($1,291.7) and drug related adverse events ($11.8) cost items, per patient annual direct medical cost related to the management of exacerbated and hospitalized COPD patients was calculated to be $3,729.9 from the payer perspective. Co-morbidities/complications (34.6%), hospitalizations/interventions (31.7%) and drug treatment/equipment (29.2%) were the key cost driver. Results: In conclusion, our findings indicate that managing exacerbated and hospitalized COPD patients pose a considerable burden to health eco- nomics in Türkiye, with co-morbidities and hospitalizations estimated as the main cost drivers. Our findings emphasize the need for cost-effective prevention strategies and the likelihood of potential cost-savings by timely recognition and proper management of co-morbidities and by better dis- ease control with reduced frequency of exacerbations and hospitalizations.","PeriodicalId":221551,"journal":{"name":"Turkiye Klinikleri Archives of Lung","volume":"197 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132583592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Akciğer Skuamöz Hücreli Karsinomlu Hastada Tiroid Metastazı Vakası

Turkiye Klinikleri Archives of Lung Pub Date : 1900-01-01 DOI: 10.5336/archlung.2022-93982

Kader Topçu, Yurdanur Süllü, Sultan Çalişkan, M. Ünsal

引用次数: 0

Primary Pulmonary Lymphoma 原发性肺淋巴瘤

Turkiye Klinikleri Archives of Lung Pub Date : 1900-01-01 DOI: 10.5336/archlung.2022-93769

Ayberk Kaan Boyacioğlu, Elçin Ersöz Köse, Enes Bayram, Abdurrahim Gördebil, Cansel Atinkaya Baytemir, İrfan Yalçınkaya, Aykut Erdagi

引用次数: 0